Kantrex Related Published Studies
Well-designed clinical trials related to Kantrex (Kanamycin)
Effects of prolonged kanamycin administration on cochlear anatomy and auditory brainstem response thresholds in chickens. [2008.05]
Topical kanamycin: an effective therapeutic option in aerobic vaginitis. [2006.08]
Well-designed clinical trials possibly related to Kantrex (Kanamycin)
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. [2009.09]
Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison. [2009.04]
Pharmacokinetics of tobramycin in ducks and sex-related differences. [2009.03]
Evaluation of polysulfated glycosaminoglycan or sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced osteoarthritis. [2009.02]
Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections. [2009.01]
A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients. [2008.12]
Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. [2008.11]
Fibrin glue versus sutures for conjunctival autografting in pterygium surgery: a prospective comparative study. [2008.09]
Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. [2008.09]
Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study. [2008.08]
Vestibular system in infants after systemic therapy with amikacin. [2008.08]
Comparison of tissue plasminogen activator-antibiotic locks with heparin-antibiotic locks in children with catheter-related bacteraemia. [2008.08]
A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. [2008.07]
Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. [2008.06]
Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India. [2008.06]
Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. [2008.05]
An evaluation of amikacin nephrotoxicity in the hematology/oncology population. [2008.03]
Comparison of two indirect techniques for local delivery of a high dose of an antimicrobial in the distal portion of forelimbs of horses. [2008.03]
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. [2008.03]
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. [2008.01]
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. [2008.01]
Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. [2007.11]
Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. [2007.09]
Control of inflammation and prophylaxis of endophthalmitis after cataract surgery: A multicenter study. [2007.09]
Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. [2007.09]
Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. [2007.09]
Phase 3 Safety Comparisons for 1.0% Azithromycin in Polymeric Mucoadhesive Eye Drops versus 0.3% Tobramycin Eye Drops for Bacterial Conjunctivitis. [2007.08]
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. [2007.07]
Effects of preoperatively selected gut decontamination on cardiopulmonary bypassjinduced endotoxemia. [2007.06]
3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. [2007.04]
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. [2007.04]
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. [2007.04]
Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis. [2007.04]
Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. [2007.03]
Efficacy and renal toxicity of one daily dose of amikacin versus conventional dosage regime. [2007.02]
Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. [2007.02]
Effect of intrathecal amikacin administration and repeated centesis on digital flexor tendon sheath synovial fluid in horses. [2007.01]
Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. [2007.01]
Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. [2007.01]
A Formulation of Aerosolized Tobramycin (Bramitob((R))) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection : A Double-Blind, Placebo-Controlled, Multicenter Study. [2007]
Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa. [2007]
Clinical Pharmacology Study of Bramitob((R)), a Tobramycin Solution for Nebulization, in Comparison with Tobi((R)). [2007]
High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients. [2006.12]
Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. [2006.12]
Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. [2006.11]
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? [2006.10]
[Comparative study between tobramicin and tobramicin plus ciprofloxacin in transrectal prostate biopsy prophylaxis] [2006.10]
Impact of ibuprofen administration on renal drug clearance in the first weeks of life. [2006.10]
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. [2006.09]
Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. [2006.07]
Effects of supplementation of beta-glucans on growth performance, nutrient digestibility, and immunity in weanling pigs. [2006.06]
Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. [2006.02]
Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. [2006.02]
Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. [2006.02]
Inhaled tobramycin in children with acute bacterial rhinopharyngitis. [2006.01]
Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. [2005.11.21]
Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II. [2005.11]
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. [2005.10.15]
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. [2005.10]
A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. [2005.09]
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. [2005.08]
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. [2005.06]
Management of diabetic foot in a Jordanian hospital. [2005.05]
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. [2005.02.12]
Prevention of acquired infections in intubated patients with the combination of two decontamination regimens. [2005.02]
Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. [2005.01]
Other research related to Kantrex (Kanamycin)
Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin. [2009.06]
A novel strategy for obtaining kanamycin resistance in Arabidopsis thaliana by silencing an endogenous gene encoding a putative chloroplast transporter. [2009.02]
[Clinical efficacy of kanamycin for Mycobacterium avium complex disease] [2008.03]
[Sensitivity to the ototoxicity of kanamycin of the rat model for mimetic aging in the inner ear] [2008.01]
Cochlear repair by transplantation of human cord blood CD133+ cells to nod-scid mice made deaf with kanamycin and noise. [2008]
Combined treatment with oral kanamycin and parenteral antibiotics for a case of persistent bacteremia and intestinal carriage with Campylobacter coli. [2008]
Pattern of cochlear damage caused by short-term kanamycin application using the round window microcatheter method. [2007.02]
Improved methods in Agrobacterium-mediated transformation of almond using positive (mannose/pmi) or negative (kanamycin resistance) selection-based protocols. [2006.08]
[A case of severe intestinal tuberculosis, treated with ciprofloxacin, kanamycin and prednisolone] [2006.04]
[Kanamycin induced ototoxicity in three kinds of mouse strains and its effects on the expression of na-K-2Cl co-transporter-1 in stria vascularis] [2006.01]
Changes in transient receptor potential cation channel superfamily V (TRPV) mRNA expression in the mouse inner ear ganglia after kanamycin challenge. [2005.03]
Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment. [2005.01]
Other possibly related research studies
Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. [2006.01]
[Severe community acquired pneumonia due to Staphylococcus aureus in children. About two cases] [2006.10]
Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. [2006.12]
New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. [2006.11]
Secondary bacterial keratitis associated with shield ulcer caused by vernal conjunctivitis. [2006.09]
Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. [2006.11]
Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. [2006.11]
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. [2006.11]
The expanding spectrum of Mycobacterium avium complex-associated pulmonary disease. [2006.10]
Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. [2006.11]
Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients. [2006.10]
Pharmacokinetics and pharmacodynamics of enrofloxacin and a low dose of amikacin administered via regional intravenous limb perfusion in standing horses. [2006.10]
Use of antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary prosthetic vascular graft infections. [2006.10]
Primary bacteraemia caused by Rhizobium radiobacter in a patient with solid tumours. [2006.10]
Chromobacterium violaceum: a case report of an unusual bacterium causing puerperal sepsis. [2006.07]
Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. [2006.11]
[Effect of the concomitant administration of indomethacin or ibuprofen on amikacin pharmacokinetics in premature newborns] [2006.05]
Acute renal failure associated with inhaled tobramycin. [2006.10.01]
Hypotonia during amikacin administration in a patient treated with continuous ambulatory peritoneal dialysis. [2006]
Efficacy and safety of meropenem plus tobramycin followed by meropenem plus vancomycin for treating peritonitis in patients on continuous ambulatory peritoneal dialysis. [2006]
Errors associated with applying decision support by suggesting default doses for aminoglycosides. [2006]
|
